| | | | | | | |

Specialized Mesothelioma Procedure Provides Long Survival, Good Life Quality

21155930_doctor2There is some good news this week for peritoneal mesothelioma patients considering cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Not only can the procedure provide long-term mesothelioma survival, but even patients who have complications experience an improved quality of life within six months.

The news is based on two newly-published studies, one conducted in France and the other in Canada.

CRS/HIPEC for Long-Term Mesothelioma Survival

Surgical oncologists at the University of Lyon have been performing CRS/HIPEC on select patients with peritoneal cancers such as mesothelioma since 1989.

In their evaluation of 1,125 procedures, including 84 mesothelioma patients, over the past 25 years, median overall survival was 42 months and improved significantly for each 5-year period.

“This study demonstrated that CRS and HIPEC provide long-term survival irrespective of PC origin, and survival improves with experience,” writes author and researcher Guillaume Passot, MD, in the Journal of Surgical Oncology.

Fourteen percent of peritoneal mesothelioma patients in the study were still alive ten years after their surgery.

Post-Surgical Quality of Life for Peritoneal Mesothelioma

Just as importantly, many mesothelioma patients who survive after CRS/HIPEC appear to also enjoy a good quality of life.

To conduct their quality of life study, researchers with the University of British Columbia and the University of Toronto reviewed data from people with peritoneal malignancies, including mesothelioma, who were treated at their institutions from 2011 to 2014.

They singled out the 42 cancer patients who had had quality of life evaluations six months after surgery.

What they found was that even patients who had major complications after CRS/HIPEC, including things like abscesses, bleeding, pleural effusion, and renal failure, were feeling as well as the people who had few complications by their 6-month evaluation.

“There were no significant differences in 6-month QOL scores between patients with and without major complications, globally or in specific domains,” writes lead author Trevor D. Hamilton, MD, in the Annals of Surgical Oncology.

CRS/HIPEC patients with uncomplicated surgeries stayed in the hospital about 13 days, while those with complications had to stay as long as 35 days.

Like all forms of mesothelioma, peritoneal mesothelioma is typically caused by exposure to asbestos. It accounts for about a fifth of the 2,500 annual mesothelioma cases in the US.

Sources:

Passot, G, et al,  “What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures”, April25, 2016, Journal of Surgical Oncology, Epud ahead of print
Hamilton, TD, et al, “Impact of Major Complications on Patients’ Quality of Life After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy”, April 19, 2016, Annals of Surgical Oncology, Epub ahead of print

Similar Posts

  • | |

    Mesothelioma survivor Paul Kraus, alive and well 19 years after writing “Surviving Mesothelioma and Other Cancers

    Paul Kraus is considered the longest documented mesothelioma survivor in the world. He was diagnosed in 1997 with mesothelioma so widespread that he was given little hope of survival. Not willing to give up, he worked with a team of doctors to create his own tailored treatment protocol. This protocol included dramatic life style change, experimental therapies, dietary changes, mind-body medicine, and other modalities. Paul was fortunate. The protocol he and his doctors created helped him keep the mesothelioma in check. His book “Surviving Mesothelioma and Other Cancers: A Patient’s Guide” details his cancer voyage, the decisions he made, and his philosophies about health and healing. This book is now the best-selling mesothelioma book in the world and has inspired…

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…